Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.33963/v.phj.104890 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
When the Tumor Leaves but the Damage Lingers: A Case of Delayed Cardiomyopathy Recovery Post-Paraganglioma Resection.
J Med Cases
August 2025
Department of Cardiology, McLaren Health Care/Michigan State University, Flint, MI, USA.
Catecholamine-induced cardiomyopathy secondary to paraganglioma is a rare and potentially reversible condition. However, the course of recovery post-resection remains variable and may be delayed despite biochemical cure. We present the case of a 47-year-old male with biopsy-confirmed extra-adrenal paraganglioma who developed acute decompensated heart failure due to catecholamine-induced cardiomyopathy (left ventricular ejection fraction (LVEF) 30-35%) and multiorgan dysfunction.
View Article and Find Full Text PDFSudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.
Eur Heart J
August 2025
Hannover Heart Rhythm Center, Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
Background And Aims: Patients with newly diagnosed non-ischaemic cardiomyopathy (NICM) or myocardial infarction/coronary artery disease (MI/CAD) face an increased risk of sudden cardiac death (SCD) during the early phase of guideline-recommended medical therapy initiation and up-titration. Aim is to evaluate the risk in this population by assessing sudden cardiac arrest (SCA) due to ventricular tachycardia/ventricular fibrillation (VT/VF).
Methods: All patients in Germany who received a wearable cardioverter-defibrillator (WCD) between December 2021 and May 2023 were enrolled in the observational multicentre SCD-PROTECT study (NCT06883383).
Should LifeVest Be Worn During Shower: A Case Report.
Cureus
July 2025
Cardiology Department, Nam Can Tho University, Can Tho, VNM.
The wearable cardioverter-defibrillator (WCD), or LifeVest (ZOLL Medical Corporation, an Asahi Kasei company, Tokyo, Japan), is designed for continuous monitoring and immediate treatment of patients at high risk of sudden cardiac arrest (SCA). Due to a lack of water resistance and inability to operate safely in wet conditions, current guidelines recommend wearing the device at all times except for short periods, such as during showering. We present the case of an 88-year-old male with complex coronary artery disease, ischemic cardiomyopathy, and permanent atrial fibrillation who experienced cardiac arrest and ventricular fibrillation (V-Fib) during a shower when not wearing his LifeVest.
View Article and Find Full Text PDFDelivery in a Pregnant Woman With Pulmonary Arterial Hypertension (PAH): A Case Report.
Cureus
July 2025
Department of Obstetrics and Perinatology, National Medical Institute of the Ministry of Interior and Administration, Warsaw, POL.
Cardiovascular diseases in pregnant women are a challenge in pregnancy and perinatal care, representing a significant cause of perinatal death among this population. In this case report, we describe a 41-year-old pregnant woman with atrial septal defect (ASD) type II, 30 mm in size, and secondary pulmonary arterial hypertension (PAH), who was admitted to the Department of Obstetrics and Perinatology for delivery at 35+5 weeks of her first pregnancy. During the first trimester, the patient's attending cardiologist decided to use a wearable cardioverter defibrillator on the patient until the end of the pregnancy and postpartum.
View Article and Find Full Text PDFA Tale of Two "Unexpected" Asystoles.
J Cardiovasc Dev Dis
July 2025
Division of Cardiology, Cardio-Thoracic Department, University Hospital of Verona, 37126 Verona, Italy.
We report two cases of prolonged "unexpected" asystoles in patients with a wearable cardioverter-defibrillator (WCD) and a subcutaneous implantable cardioverter-defibrillator (ICD), respectively, which were promptly recognized and successfully managed. As these devices are designed to recognize and treat malignant tachyarrhythmias but do not provide pacing capabilities, it is crucial to identify patients with paroxysmal conduction disorders who might require backup pacing. For this reason, it is also important to leverage the monitoring features of both devices and their ability to detect the occurrence of bradyarrhythmias.
View Article and Find Full Text PDF